· Murai H, Uzawa A, Suzuki Y, Imai T, Shiraishi H, Suzuki H, Okumura M, O'Brien F, Wang JJ, Fujita KP, Utsugisawa K; REGAIN Study Group. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. J Neurol Sci. 2019 Aug 3;407:116419. doi: 10.1016/j.jns.2019.08.004.

· Andersen H, Mantegazza R, Wang JJ, O'Brien F, Patra K, Howard JF Jr; REGAIN Study Group.Eculizumab improves fatigue in refractory generalized myasthenia gravis. Qual Life Res. 2019 Aug;28(8):2247-2254. doi: 10.1007/s11136-019-02148-2.

· Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF Jr; Regain Study Group.Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019 Jul;60(1):14-24.

· İnan B, Bekircan-Kurt CE. Yıldız FG, Erdem-Özdamar S, Giant cell myositis associated with myasthenia gravis and thymoma. Neurol Sci Neurophysiol 2019 DOI: 10.5152/NSN.2019.12570

· Meltem Koca, Abdulsamet Erden, Berkan Armagan, Alper Sari, Fatih Yildiz, Sevim Ozdamar, Umut Kalyoncu & Omer Karadag (2019) Two cases of glutaric aciduria type II:how to differentiate from inflammatory myopathies?, Acta Clinica Belgica, 74:6, 451-455,

· Karanfil E, Salcı Y, Fil-Balkan A, Bekircan-Kurt CE,Erdem Özdamar S, Armutlu K. Reliability and Validity of Turkish Myasthenia Gravis-Activities of Daily Living Scale. OTJR (Thorofare N J). 2020 Oct 3:1539449220961077. doi: 10.1177/1539449220961077.

· Mantegazza R, O'Brien FL, Yountz M, Howard JF Jr; REGAIN study group. Consistent improvement with eculizumab across muscle groups in myasthenia gravis.Ann Clin Transl Neurol. 2020 Aug;7(8):1327-1339. doi: 10.1002/acn3.51121.

· Vissing J, Jacob S, Fujita KP, O'Brien F, Howard JF; REGAIN study group.'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol. 2020 Jul;267(7):1991-2001. doi: 10.1007/s00415-020-09770-y.

· Bulduk BK, Kiliç HB, Bekircan-Kurt CE, Haliloğlu G,Erdem Özdamar S, Topaloğlu H, Kocaefe YÇ. A Novel Amplification-Refractory Mutation System-PCR Strategy to ScreenMT-TL1Pathogenic Variants in Patient Repositories.Genet Test Mol Biomarkers. 2020 Mar;24(3):165-170. doi: 10.1089/gtmb.2019.0079.

· Okar SV, Bekircan-Kurt CE, Hacıoğlu S,Erdem-Özdamar S, Özkul A, Ergünay K. Toscana virus associated with Guillain-Barré syndrome: a case-control study.Acta Neurol Belg. 2020 Jan 22. doi: 10.1007/s13760-020-01279-5.

· Can Ebru Bekircan-Kurt,Çağrı Temuçin,Şule Apraş Bilgen,Sevim Erdem-Ozdamar. Trigeminal sensory-motor neuropathy in a patient with mixed connective tissue disease and review of the literature. Neurological Sciences and Neurophysiology 2020 37: 148-151.

· Pekgül F, Eroğlu-Ertuğrul NG, Bekircan-Kurt CE, Erdem-Ozdamar S, ÇetinkayaA, Tan E, KonuşkanB, KaraağaoğluE, TopçuM, Akarsu NA,OguzKK,AnlarB, ÖzkaraHA. Comprehensive clinical, biochemical, radiological and genetic analysis of 28 Turkish cases with suspected metachromatic leukodystrophy and their relatives. Mol Genet Metab Rep. 2020.

· Mehdikhanova L, Bekircan – Kurt CE, Tunali G, Tuncer A, Önder S, Karabulut E, Yılmaz M, Esendagli G, Erdem-Ozdamar S. NK and Th17 Cells in The Thymus of Myasthenia Gravis Patients. Acta Medica 2020; 51(3): 9 – 17. (Indexed in: Google Scholar ve ULAKBİM TR-Dizin)

· Mantegazza R, Wolfe GI, Muppidi S, Wiendl H, Fujita KP, O'Brien FL, Booth HDE, Howard JF Jr; REGAIN Study Group.Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.Neurology. 2021 Jan 26;96(4):e610-e618. doi: 10.1212/WNL.0000000000011207.

· Aksu-Menges, Balci-Hayta, B ; Bekircan-Kurt, CE; Aydinoglu, AT; Erdem-Ozdamar, S; Tan, E Two distinct skeletal muscle microRNA signatures revealing the complex mechanism of sporadic ALS. Acta Neurologica Belgica.

· Bekircan-Kurt CE, Çetinkaya A, Gocmen R, Koşukcu C, Soylemezoglu F, Arsava EM, Tuncer A,Erdem-Ozdamar S, Akarsu NA, Topcuoglu MA. One Disease with two Faces: Semidominant Inheritance of a Novel HTRA1 Mutation in a Consanguineous Family. J Stroke Cerebrovasc Dis. 2021 Sep;30(9):105997. doi: 10.1016/j.jstrokecerebrovasdis.2021.105997.

· Diaz-Manera J, Kishnani PS, Kushlaf H, Ladha S, Mozaffar T, Straub V, Toscano A, van der Ploeg AT, Berger KI, Clemens PR, Chien YH, Day JW, Illarioshkin S, Roberts M, Attarian S, Borges JL, Bouhour F, Choi YC,Erdem-Ozdamar S, Goker-Alpan O, Kostera-Pruszczyk A, Haack KA, Hug C, Huynh-Ba O, Johnson J, Thibault N, Zhou T, Dimachkie MM, Schoser B; COMET Investigator Group. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol. 2021 Dec;20(12):1012-1026. doi: 10.1016/S1474-4422(21)00241-6.

· Siddiqi ZA, Nowak RJ, Mozaffar T, O'Brien F, Yountz M, Patti F; REGAIN Study Group. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study.Muscle Nerve. 2021 Dec;64(6):662-669. doi: 10.1002/mus.27422.

· Karanfil E, Salcı Y, Fil-Balkan A, Bekircan-Kurt CE,Erdem Özdamar S, Armutlu K Reliability and Validity of Turkish Myasthenia Gravis-Activities of Daily Living Scale. OTJR (Thorofare N J). 2021 Apr;41(2):101-107. doi: 10.1177/1539449220961077.

· Bekircan-Kurt CE, Yilmaz E, Arslan D, Yildiz FG, Dikmetas Ö, Ergul-Ulger Z, Kocabeyoglu S, Irkec M, Hekimsoy V, Tokgozoglu L, Tan E,Erdem-Ozdamar S.The functional and structural evaluation of small fibers in asymptomatic carriers of p.Val50Met (Val30Met) mutation.Neuromuscul Disord. 2021 Dec 2:S0960-8966(21)00718-5. doi: 10.1016/j.nmd.2021.11.013.

· Bekircan-Kurt CE, Inan B, Bulut O, Şengün İ, Karli N, Güneş N, Çokal BG, Güler SK, Yoldaş TK, Özcanyüz DG, Koç F, Ünlütürk Z, Erdoğan Ç, Uludağ B, Boz C, Tütüncü M, Akalin MA, Kamişli Ö, Özcan A, Koytak PK, Uluç K,Erdem-Özdamar S, Tan E.Neuropathic Pain Frequency in Neurology Outpatients: A Multicenter Study. Noro Psikiyatr Ars. 2021 Nov 15;58(4):257-260. doi: 10.29399/npa.27549.

· İnan B, bekircan-Kurt CE, Akça O, Erdem-Ozdamar S, Tan E. Cane sign: Sciatic neuropathy appearance in magnetic resonance imaging. RRNMF Neuromuscular Journal 2021: 2 (1): 41-42.

· James F Howard Jr1,Chafic Karam2,Marcus Yountz3,Fanny L O'Brien3,Tahseen Mozaffar4,REGAIN Study Group Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses Ann Clin Transl Neurol.2021 Jul;8(7):1398-1407. doi: 10.1002/acn3.51376.

· Ceren AN, Salcı Y, Fil Balkan A, Kütükçü EÇ, Armutlu K, Erdem-Ozdamar S. The effects of spinal stabilization exercises in patients with myasthenia gravis: a randomized crossover study. Disabil Rehabil. 2022 Jan 3:1-8. doi: 10.1080/09638288.2021.2022221.

· Bekircan-Kurt CE, Yılmaz E, Arslan D, Yildiz FG, Dikmetas Ö, Ergul-Ulger Z, Kocabeyoglu S, Irkec M, Hekimsoy V, Tokgozoglu L, Tan E, Erdem-Ozdamar S. The functional and structural evaluation of small fibers in asymptomatic carriers ofTTRp.Val50Met (Val30Met) mutation. Neuromuscular Disorders, 2022: 32: 50-56. Doi: 10.1016/j.nmd.2021.11.013

· Inan B, Bekircan-Kurt CE, Ergul-Ulger Z, Yilmaz M, Dikmen ZG, Arsava EM, Topcuoglu MA, Caglar O, Basol M, Karaagaoglu E,Erdem-Ozdamar S, Tan E, Temucin CM Multimodal assessment of intensive care unit-acquired weakness in severe stroke patients. .Acta Neurol Belg. 2022 Oct;122(5):1313-1321. doi: 10.1007/s13760-022-02009-9.

· Dumbak AB, Kayıkçı MEK, Şahin Mİ, Kuşçu O, Bekircan-Kurt CE, Erdem-Ozdamar S. Comprehensive evaluation of velopharyngeal function in myasthenia gravis patients. Acta Neurol Belg Oct;122(5):1229-1236. doi: 10.1007/s13760-022-01904-5.

· Demirci C. S.,Sütçü G.,Ayvat F.,Onursal Kilinç Ö.,Doğan M.,Ayvat E.KURT C. E. , ERDEM ÖZDAMAR S., Yildirim S. A. , KILINÇ M et al. ,Identifying a Cut-off Point for Timed Up and Go Test in Neuromuscular Diseases. turkısh Journal Of Neurology, cilt.28, sa.1, ss.6-9, 2022

· Berin İnan, Can Ebru Bekircan‑Kurt, Haluk Demiroğlu1 , Hakan Göker1 , Sevim Erdem‑Özdamar, Ersin TanAutologous Stem Cell Transplantation in a Patient with Refractory Anti‑MuSK‑Positive Myasthenia Gravis and Familial Mediterranean Fever. Neurological Sci Neurophysiology 2022: 39 (2) April-June, 115-118. SCIE, Q4.

· Arslan D, Inan B, Kilinc M, Bekircan-Kurt CE,Erdem-Ozdamar S, Tan E. Nusinersen for adults with spinal muscular atrophy. Neurol Sci. 2023 Mar 1. doi: 10.1007/s10072-023-06698-9.

· Bekircan-Kurt CE, Jahanroshan J, Tuncer A, Ergul-Ulger Z, Gunes G,Erdem-Ozdamar S, Tan E The evaluation of small fibers in multiple sclerosis. Mult Scler Relat Disord. 2023 Apr;72:104602. doi: 10.1016/j.msard.2023.104602.

· Kishnani PS, Diaz-Manera J, Toscano A, Clemens PR, Ladha S, Berger KI, Kushlaf H, Straub V, Carvalho G, Mozaffar T, Roberts M, Attarian S, Chien YH, Choi YC, Day JW,Erdem-Ozdamar S, Illarioshkin S, Goker-Alpan O, Kostera-Pruszczyk A, van der Ploeg AT, An Haack K, Huynh-Ba O, Tammireddy S, Thibault N, Zhou T, Dimachkie MM, Schoser B; COMET Investigator Group. Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial. JAMA Neurol. 2023 Apr 10. doi: 10.1001/jamaneurol.2023.0552.

·

·

/* Style Definitions */ table.MsoNormalTable { line-height:107%; font-size:11.0pt; font-family:"Calibri","sans-serif"; }

Neuromuscular disorders.

:

: sevime@hacettepe.edu.tr